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educing racial/ethnic disparities in various diseases, with racial/ethnic minority group members having higher rates of disease, has long been a high priority of the US Department of Health and Human Services and the National Institutes of Health. 1 The HIV/AIDS epidemic among persons who inject drugs (PWID) is a notable example of racial/ethnic disparities: African Americans constitute 13% of the US population and 48% of AIDS cases among PWID; Latino/as (Hispanics) constitute 17% of the US population and 28% of AIDS cases among PWID; nonHispanic Whites constitute 63% of the US population and 20% of AIDS cases among PWID. 2, 3 For 2011, estimated rates of HIV infection among PWID were 32 per 100 000 for Whites, 284 per 100 000 for African Americans, and 144 per 100 000 for Latino/as. 4 Reducing HIV among PWID has been one of the notable successes in HIV prevention in the United States. Estimated HIV incidence among PWID fell by approximately 80% from 1996 through 2011, 5 and there was an additional 83% reduction in newly diagnosed cases of HIV among PWID between 2005 and 2014. 6 These large reductions in HIV transmission among PWID raise the question of whether the racial/ethnic disparities in HIV infection among PWID can be eliminated. With more than 60 000 cumulative cases of AIDS among PWID, 7 New York City has experienced the largest HIV/AIDS epidemic among PWID of any city in the world. HIV was introduced into the PWID population in New York City in the mid-1970s, and spread rapidly with prevalence rising to more than 50% by 1981. 8 Large racial/ethnic disparities emerged, with African American and Latino/ a PWID having approximately twice the HIV prevalence of White PWID. 9 These disparities persisted during the period of stable HIV prevalence-from the mid-1980s through the early 1990s, and during the period of large-scale implementation of syringe exchange in the mid-1990s, when HIV prevalence fell among PWID to 17% and HIV incidence fell to 0.8 per 100 person-years. 10 Racial/ethnic differences in HIV prevalence are not associated with individual-level injection behaviors, 11 but there are other factors that may promote persistent disparities. First, a longer time period may be needed to reach full effectiveness of combined prevention and care among racial/ethnic minority PWID. Racial/ethnic minority PWID had much higher rates of HIV infection when combined prevention was first implemented during the mid-1990s. It may simply take more time to reach minimum transmission among minority groups. Second, there are risk network and structural factors that may limit the effectiveness of current interventions to reduce injecting-related HIV transmission among racial/ethnic minority PWID. 12 These could include higher-risk injection networks (larger, denser, more rapid turnover) and structural factors such as stigmatization, poverty, and less access to sterile injection equipment. Third, PWID may acquire HIV through unsafe sexual activity as well as through sharing injection equipment. Modeling of HIV transmission by using HCV rates among PWID in New York City suggests that two thirds of new HIV infections among PWID are attributable to sexual transmission. 13 Sexual transmission of HIV in New York City is higher among both racial/ethnic minority "high-risk heterosexuals" and racial/ ethnic minority men who have sex with men (MSM), 14 so that the same factors that lead to higher rates of sexual transmission among racial/ethnic minority persons who do not inject may also create higher sexual transmission among racial/ethnic minority PWID.
The first of these factors-more time needed-would predict reductions over time and eventual elimination of the disparities. The second factor (risk network and social structural differences) would predict that disparities persist as long as these network and structural factors persist. The third (differences in sexual transmission) would predict that the disparities would persist as long as disparities in sexual transmission persist.
We examined racial/ethnic disparities in HIV infection at the "end of the HIV epidemic" among PWID in New York City. "End of the epidemic" 15 does not mean a total absence of HIV infection. On the basis of multisite studies of cities in which effective HIV prevention was provided very early and HIV prevalence remained at very low levels 16 and studies in high-prevalence settings in which combined prevention and care interventions led to large reductions in HIV transmission, 17 we propose the following as an operational definition of an "end to an HIV epidemic" among PWID:
1. The prevalence of untreated HIV infection is 5% or less. 2. HIV incidence is 0.5 per 100 person-years or less.
We first describe changes in HIV infection among PWID in New York City from 2001-2005 to 2011-2015, and then examine multiple measures of racial/ethnic disparities among PWID. Using herpes simplex virus 2 (HSV-2) as a biomarker for high sexual risk, we also examine whether differential sexual transmission may be contributing to disparities in HIV. HSV-2 is transmitted sexually and biologically increases susceptibility to and transmissibility of HIV by a factor of 2 to 3.
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It is a major factor for HIV transmission in Sub-Saharan Africa and among noninjecting drug users in New York City. 19 
METHODS
The data presented here were collected as part of a long-running research study of persons entering Mount Sinai Beth Israel drug detoxification and methadone maintenance programs in New York City. 20 The programs serve New York City as a whole and there were no changes in the entrance requirements over the study period.
Participant Recruitment
In the detoxification program, research staff visited the general admission wards of the program in a preset order and examined all intake records of a specific ward to construct lists of patients admitted within the previous 3 days. Assignments of new patients to the wards were based on open beds available at the time that new patients are admitted. All of the patients admitted in the previous 3 days to the specific ward were asked to participate in the study. As there was no relationship between the assignment of patients to wards and the order that the staff rotated through the wards, these procedures should produce an unbiased sample of persons entering the program. In the methadone program, newly admitted patients (those admitted in the previous month) were asked to participate in the research.
Participants were paid $20 for their time and effort. In both programs, approximately 95% of those asked agreed to participate. Common reasons for nonparticipation included medical appointments or other scheduled activities that would not permit completion of the study in a single visit.
Data Collection
Written informed consent was obtained and a trained interviewer administered a computer-assisted structured questionnaire covering demographics, drug use, risk behavior, and use of HIV prevention services. In the analyses presented here, only persons who reported having injected drugs in the 6 months before program entry are included. To classify individuals by race/ethnicity, participants were asked, "With what racial or ethnic group do you most identify?" Respondents were able to respond with 1 specific racial or ethnic group, or as "mixed racial/ethnic group." Because the sample sizes for Asian, Native Hawaiian/Pacific Islander, American Indian/Alaska Native, and "mixed" were too small for statistical testing (< 5% in total), we included persons who identified as White, African American, and Latino/a in the analyses. Participants were also asked if they had ever been tested for HIV, and results of their most recent test. Those who replied that they had tested HIV seropositive were then asked if they had received antiretroviral treatment (ART) in the previous 6 months. More than 98% reported that they had been previously tested for HIV.
Participants were seen by counselors for HIV pretest counseling and serum collection. HIV testing was conducted at the New York City Department of Health Laboratory with a commercial enzyme-linked immunosorbent assay test with Western blot confirmation (BioRad Genetic Systems HIV-1/HIV-2+O EIA and HIV-1 Western Blot, BioRad Laboratories, Hercules, CA). Beginning in 2005, HSV-2 testing was conducted for all participants and was performed by BioReference Laboratories with the Focus HerpeSelect 1 and 2 enzyme-linked immunosorbent assay (Focus Diagnostics, Cypress, CA). We used an index value of 1.1 or greater for classifying a participant as HSV-2 seropositive. We used HSV-2-HIV coinfection as an operational definition of "high risk for HIV transmission." 19 
Data Analyses
We compared data from PWID who participated in the Risk Factors study from 2001 to 2005 to data from PWID who participated from 2011 to 2015 to examine potential change over time in racial/ethnic disparities in HIV infection. We selected these time periods because we have data on the decline in HIV incidence for these approximate periods, from 0. As a sensitivity analysis, we also conducted analyses with all data from multiple participants; the results were always within 1% of the results reported here, and results of all of the statistical significance tests were the same.)
We also used New York City Department of Health and Mental Hygiene (DOHMH) surveillance data on newly diagnosed cases of HIV among PWID (excluding MSM-PWID) to estimate incidence among PWID in New York City. 22 We used multivariable logistic modeling, with control for age, gender, and recruitment site, to assess whether the racial/ethnic disparities in HIV seroprevalence were similar across the 2 time periods. We did not control for recent HIV risk behaviors because of the likelihood that HIV seropositives knew their status and had reduced their risk behaviors to reduce possible transmission to injecting and sexual partners. 23 We also conducted stratified analyses on HSV-2 serostatus; as noted previously, we used HSV-2 seropositive status as an operational definition for high-risk sexual transmission of HIV.
We used Stata software version 14 (StataCorp LP, College Station, TX) for statistical analyses.
RESULTS
We first present information on changes in our PWID samples over time, then examine multiple measures of disparities in HIV prevalence, and then disparities in estimated HIV incidence.
Demographic Characteristics, Drug Use, and HIV Seroprevalence Comparison of HIV prevalence across the time periods shows a reduction of approximately half in each of the racial/ethnic groups, but with significant racial/ethnic differences in each time period. We used multivariable logistic regression to examine whether the racial/ethnic differences remained significant after we controlled for age and gender. Results are presented in Table 1 , which shows the adjusted odds ratios (AORs) for race/ ethnicity (HIV prevalence among African Americans compared with Whites and HIV prevalence among Latino/as compared with Whites). Table 1 Table 2 presents the percentages of PWID in each racial/ethnic group with untreated HIV infection-persons who were both HIV seropositive and not receiving ART. There were statistically significant reductions across the time periods, but also significant differences by race/ethnicity in both time periods. These differences in the prevalence of untreated HIV infection can be considered an important indicator of continuing racial/ ethnic disparities.
Herpes Simplex Virus 2 and Risk for HIV Sexual Transmission
As noted in the Methods, we also tested for HSV-2, a biomarker of high risk for sexual transmission of HIV. Table 3 The comparisons that included coinfected participants showed statistically significant differences by race/ethnicity, whereas none of the comparisons limited to HIV monoinfection were statistically significant.
Estimated HIV Incidence
Newly diagnosed cases of HIV infection are frequently used to estimate HIV incidence. In New York City, cases of newly diagnosed HIV infection among PWID are consistent with other measures of HIV incidence. 21 Table 4 presents newly diagnosed cases of HIV among PWID in New York City (excluding MSM-PWID) for the 2001 to 2005 and 2011 to 2015 time periods. There has been a substantial reduction in the total numbers of newly diagnosed cases of HIV among PWID in New York City, with reductions in all major racial/ethnic groups. The reductions have been similar among all 3 major racial/ethnic groups (note that there are no significant trends in the percentages of cases among the 3 major groups). There is a suggestion of reaching a floor effect in 2013 to 2015, as the total numbers of new cases are almost identical for these 3 years (41, 42, and 39 cases, respectively).
These new diagnoses are not adjusted for the denominators of the number of PWID in each racial/ethnic group. We estimated denominators for the major racial/ethnic groups of PWID on the basis of a published estimate of approximately 100 000 PWID and a distribution of 20% White, 30% Black, and 50% Latino/a in New York City. 24 This gave estimated HIV incidence rates of 2 per 10 000 person-years for Whites, 4 per 10 000 personyears for African Americans, and 4 per 10 000 person-years for Latino/as. (As the numbers of newly diagnosed cases are exact counts reported to HIV Surveillance Unit at the DOHMH and are not based on sampling, standard statistical testing is not appropriate.) The HIV Surveillance Unit does not obtain HSV-2 data for newly identified cases of HIV among PWID, so it is not possible to do stratified incidence estimates by HSV-2 infection.
DISCUSSION
By the criteria proposed in the introduction, the data presented here indicate that the HIV epidemic has ended among all 3 major racial/ethnic groups of PWID in New York City. Prevalence of untreated HIV infection is less than 5% and HIV incidence is less than 0.5 per 100 person-years.
Despite this progress, racial/ethnic disparities still exist in the prevalence of untreated HIV infection and in estimated HIV incidence (both lowest among Whites and highest among African Americans). The disparities in HIV prevalence are concentrated among HSV-2 seropositive PWID at high risk for sexual transmission (HIV-HSV-2 coinfected).
In the introduction, we noted 3 hypotheses for racial/ethnic disparities in HIV among PWID in New York City. In our assessment, our data provide the least support for the "more time is needed" hypothesis. There was no reduction in the AORs for racial/ethnic disparities in HIV prevalence between 2001 to 2005 and 2011 to 2015 and the disparities in estimated HIV incidence also did not decrease.
The data presented provide the most support for the third hypothesis-that persistence in the disparities is associated with sexual transmission of HIV. Infection with HSV-2 clearly differentiates HIV-infected PWID into a group with substantial and statistically significant racial/ethnic disparities versus a group with very modest and nonsignificant disparities. In fact, HSV-2 facilitates both sexual acquisition and transmission of HIV by a factor of 2 to 3 18 and is significantly more prevalent among racial/ethnic minority PWID. Furthermore, modeling of recent HIV infections in New York City suggests that approximately two thirds of these are attributable to sexual transmission. 13, 25 Our focus on the potential role of sexual transmission is not meant to contradict the potential importance of social network and social structural factors in persistence of the racial/ethnic disparities among PWID. Rather, we suspect that these factors operate in conjunction with high sexual risk to generate persistent disparities among PWID. Infection with HSV-2, which we used as an operational definition of high sexual risk, is twice as prevalent among African Americans as among Whites in the general US population. 26 Racial/ethnic disparities exist for many sexually transmitted infections in the United States, 27 including HIV among MSM and among "high risk heterosexuals," 28, 29 and we suspect that the social network and social structural factors, including HSV-2 infection, 26 generating these disparities are operating among PWID as well as persons who do not inject drugs. Indeed, that risk network and social structural factors operating in conjunction with sexual risk lead to persistence of racial/ethnic disparities among PWID in New York City may be both the most comprehensive and parsimonious explanation for our results.
Limitations
Several limitations of this study should be noted. First, all of the participants in the study were recruited from the Mount Sinai Beth Israel drug treatment programs. Thus, we would not generalize to PWID whose injecting drug use has not been sufficiently problematic for them to seek formal treatment. We would also not generalize to PWID populations without HSV-2 or other sexually transmitted infections that facilitate HIV transmission. Previous comparisons to our participants recruited from community sites and other drug treatment programs have, however, shown great consistency in absolute values and in trends between the data from Mount Sinai Beth Israel and the data from other New York City recruitment sites. 30, 31 There was also consistency in the reductions in HIV infection among PWID in the Risk Factors data reported here and in the numbers of newly identified cases of HIV among PWID from the HIV Surveillance Unit at DOHMH (Table 4) . Most importantly, a recent comparison of HIV incidence estimates from the DOHMH, the New York State Department of Health, and the Risk Factors study showed great consistency in the estimates-all were with a range of 0.2 per 100 person-years and great overlap in the 95% confidence intervals. 21 Second, we do not yet have viral load data for our HIV seropositive participants who reported receiving ART. Viral load data would permit us to calculate "population viral load" for the different racial/ethnic groups. 32 Disparities in reaching viral suppression may be occurring among PWID receiving ART in New York City.
Third, we had modest numbers of HIV seropositives and very modest numbers of newly identified cases of HIV infection for 2011 to 2015. These small numbers are clearly a very positive development, but they do not permit complex statistical analyses.
We do not have data on risk behavior or HSV-2 status at the time of HIV infection, so we cannot assess the possibility of differences in risk behavior or HSV-2 status immediately before infection. However, because both viruses produce lifelong seropositivity, the associations between race/ethnicity and HIV and HSV-2 infection must be considered valid.
Although these are important limitations, it would seem unlikely that the consistency between our Risk Factor data and other data from New York City, particularly the DOHMH surveillance data, arose from these limitations. Rather, it would appear that the consistency across the data sources reflects existing trends in HIV infection among PWID in New York City. It would also seem highly unlikely that the variation in racial/ethnic disparities by HSV-2 infection status arose from the limitations, but also reflects the processes that lead to racial/ ethnic disparities.
Conclusions
We suggest several directions for future research and interventions for reducing the disparities we observed. First, in terms of specific interventions for HIV, we would suggest additional focus on PWID at high risk for HIV transmission, including expansion of ART as prevention to eliminate disparities in the prevalence of untreated HIV infection. At a more general level, we need further research and intervention development related to the social network and structural factors that may generate higher rates of sexually transmitted infections among minority groups.
Like many other areas of the United States, New York City is experiencing increasing rates of drug injecting, as persons transition from oral use of opioid analgesics to injecting opioids and heroin. Disparities in this new epidemic may arise along economic lines rather than racial/ethnic lines (e.g., the outbreak in Scott County, IN). 33 Avoiding a resurgence in injecting-related HIV transmission should be a high priority.
Research is also needed to determine if it will be possible to reduce disparities in HIV infection in other locations in the United States and in many other countries, particularly in low-and middle-income countries.
11
In resource-limited settings, ethnic-minority PWID may be at considerable risk for acquiring sexually transmitted infections that facilitate HIV transmission and of not receiving adequate prevention and care services.
Racial/ethnic disparities in HIV infection among PWID have been observed in many countries and other locations in the United States. 11, 33 The New York City experience shows that combined prevention and care can lead to an "end of the epidemic" in all major racial/ethnic groups, but with persistence of racial/ethnic disparities. Eliminating disparities may require additional focus on PWID at high risk for sexual transmission of HIV. 
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